Cargando…

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

BACKGROUND: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Yoko, Matsubara, Nobuaki, Tabata, Ken-ichi, Satoh, Takefumi, Kamiya, Naoto, Suzuki, Hiroyoshi, Kawahara, Takashi, Uemura, Hiroji, Yano, Akihiro, Kawakami, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069876/
https://www.ncbi.nlm.nih.gov/pubmed/27756383
http://dx.doi.org/10.1186/s13104-016-2279-9
_version_ 1782461023903547392
author Yamada, Yoko
Matsubara, Nobuaki
Tabata, Ken-ichi
Satoh, Takefumi
Kamiya, Naoto
Suzuki, Hiroyoshi
Kawahara, Takashi
Uemura, Hiroji
Yano, Akihiro
Kawakami, Satoru
author_facet Yamada, Yoko
Matsubara, Nobuaki
Tabata, Ken-ichi
Satoh, Takefumi
Kamiya, Naoto
Suzuki, Hiroyoshi
Kawahara, Takashi
Uemura, Hiroji
Yano, Akihiro
Kawakami, Satoru
author_sort Yamada, Yoko
collection PubMed
description BACKGROUND: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated with docetaxel. However, data on the antitumor activity of AA as a second androgen receptor-targeting new agent after the failure of enzalutamide in chemotherapy-naive mCRPC patients is unavailable. METHODS: Patients with chemotherapy-naïve mCRPC who were treated with AA after disease progression with enzalutamide, were retrospectively reviewed at five institutions. Primary outcome measure was the rate of any prostate-specific antigen (PSA) decline. Secondary outcome measures were progression-free survival (PFS) and overall survival (OS) with subsequent AA treatment. We also performed correlation analysis between previous PSA response, PFS duration to enzalutamide and subsequent PSA response, PFS duration to AA. RESULTS: A total of 14 patients were identified. Any PSA declines and PSA decline ≥50 % with AA treatment, were observed in 36 and 7 % of patients, respectively. Median PFS with initial enzalutamide was 5.0 months (95 % CI 3.7–6.4 months), and for subsequent AA treatment was 3.4 months (95 % CI 0.8–6.0 months). Median OS from initiation of AA was 9.1 months (95 % CI 5.6–12.5 months). No significant correlations were observed between these PSA responses (Pearson r = −0.67, p = 0.82) and PFS duration (Kendall tau r = 0.33, p = 0.87). CONCLUSIONS: The PSA decline with subsequent AA treatment in chemotherapy-naive mCRPC patients after a failure of enzalutamide was modest, however, the PFS and OS with subsequent AA treatment were comparable to those of enzalutamide previously reported as a second androgen receptor-targeting new agent after AA failure. The PSA response and PFS duration to previous enzalutamide treatment did not predict those of subsequent AA treatment.
format Online
Article
Text
id pubmed-5069876
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50698762016-10-24 Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis Yamada, Yoko Matsubara, Nobuaki Tabata, Ken-ichi Satoh, Takefumi Kamiya, Naoto Suzuki, Hiroyoshi Kawahara, Takashi Uemura, Hiroji Yano, Akihiro Kawakami, Satoru BMC Res Notes Research Article BACKGROUND: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Several retrospective analysis suggested clinical cross-resistance between these agents in patients previously treated with docetaxel. However, data on the antitumor activity of AA as a second androgen receptor-targeting new agent after the failure of enzalutamide in chemotherapy-naive mCRPC patients is unavailable. METHODS: Patients with chemotherapy-naïve mCRPC who were treated with AA after disease progression with enzalutamide, were retrospectively reviewed at five institutions. Primary outcome measure was the rate of any prostate-specific antigen (PSA) decline. Secondary outcome measures were progression-free survival (PFS) and overall survival (OS) with subsequent AA treatment. We also performed correlation analysis between previous PSA response, PFS duration to enzalutamide and subsequent PSA response, PFS duration to AA. RESULTS: A total of 14 patients were identified. Any PSA declines and PSA decline ≥50 % with AA treatment, were observed in 36 and 7 % of patients, respectively. Median PFS with initial enzalutamide was 5.0 months (95 % CI 3.7–6.4 months), and for subsequent AA treatment was 3.4 months (95 % CI 0.8–6.0 months). Median OS from initiation of AA was 9.1 months (95 % CI 5.6–12.5 months). No significant correlations were observed between these PSA responses (Pearson r = −0.67, p = 0.82) and PFS duration (Kendall tau r = 0.33, p = 0.87). CONCLUSIONS: The PSA decline with subsequent AA treatment in chemotherapy-naive mCRPC patients after a failure of enzalutamide was modest, however, the PFS and OS with subsequent AA treatment were comparable to those of enzalutamide previously reported as a second androgen receptor-targeting new agent after AA failure. The PSA response and PFS duration to previous enzalutamide treatment did not predict those of subsequent AA treatment. BioMed Central 2016-10-18 /pmc/articles/PMC5069876/ /pubmed/27756383 http://dx.doi.org/10.1186/s13104-016-2279-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yamada, Yoko
Matsubara, Nobuaki
Tabata, Ken-ichi
Satoh, Takefumi
Kamiya, Naoto
Suzuki, Hiroyoshi
Kawahara, Takashi
Uemura, Hiroji
Yano, Akihiro
Kawakami, Satoru
Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title_full Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title_fullStr Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title_full_unstemmed Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title_short Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
title_sort abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069876/
https://www.ncbi.nlm.nih.gov/pubmed/27756383
http://dx.doi.org/10.1186/s13104-016-2279-9
work_keys_str_mv AT yamadayoko abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT matsubaranobuaki abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT tabatakenichi abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT satohtakefumi abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT kamiyanaoto abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT suzukihiroyoshi abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT kawaharatakashi abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT uemurahiroji abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT yanoakihiro abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis
AT kawakamisatoru abirateroneacetateafterprogressionwithenzalutamideinchemotherapynaivepatientswithmetastaticcastrationresistantprostatecanceramulticenterretrospectiveanalysis